Skip to main content Skip to main content
Go to homepage

Safety and efficacy of Ravulizumab

Safety and efficacy of Ravulizumab for pediatric patients with thrombocytic microangiopathy following hematopoetic stem cell transplantation


View complete study details here.

Interested in participating?
We are currently recruiting
Study Sponsor:

Alexion Pharmaceuticals, Inc.

Full IRB Study Title:
ALXN1210-TMA-314: A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)
IRB Study ID:
If you are interested in this study or have questions about your child's eligibility, please contact:

Showers Family Center for Childhood Cancer and Blood Disorders. 330-543-8730

Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research, Shannon E. Wilkes Targeted Therapy Program; The Jeffrey A. Barbour Chair for Pediatric Hematology/Oncology Research and Healing; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.